The new frontiers of DMT therapies

In today’s episode, we explore the therapeutic application of DMT across a range of diseases and conditions including Alzheimer’s, stroke, and organ transplants. While much of the attention in psychedelic medicine has been on their ability to address neuropsychiatric indications, research suggests that psychedelics like DMT have a far wider therapeutic potential. The episode features three biotech companies developing DMT therapies:  Algernon, Psilera, and Pharmadrug.In this episode, we discuss:DMT therapies for organ transplants, stroke patients and substance abuse disordersResearch supporting NN-DMT’s antioxidative and anti-inflammatory effects and the receptors it targetsBeing a private company vs. public company in psychedelicsNN-DMT5-MeO-DMTBioavailabilityDMT transdermal patchSigma-1DonepezilDr. Rick StrassmanAngiogenesisOrphan Drug DesignationCreated by Greg Kubin and Matias SerebrinskyHost: Matias SerebrinskyProduced by Jonathan A. Davis & Zack FrankMarketing by DaisyMae VanValkenburghRead the transcript here.Find us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional music: Copley Beat by Blue Dot Sessions, Simplify by Little Glass Men, Pedalrider by Blue Dot Sessions, Running Waters by Jason Shaw, and Neon Drip by Blue Dot Sessions